VIP943

Near Add Your Location

Sorting 1 by

Accepting patients

VIP943

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
Learn more
  • Antibody Drug Conjugate (ADC)
  • Kinesin Spindle Protein (KSP) Inhibitor
  • CD123
  • Phase 1